IL181694A0 - Beta glycolipids for the treatment of neurodegenerative disorders - Google Patents

Beta glycolipids for the treatment of neurodegenerative disorders

Info

Publication number
IL181694A0
IL181694A0 IL181694A IL18169407A IL181694A0 IL 181694 A0 IL181694 A0 IL 181694A0 IL 181694 A IL181694 A IL 181694A IL 18169407 A IL18169407 A IL 18169407A IL 181694 A0 IL181694 A0 IL 181694A0
Authority
IL
Israel
Prior art keywords
treatment
neurodegenerative disorders
glycolipids
beta
beta glycolipids
Prior art date
Application number
IL181694A
Original Assignee
Hadasit Med Res Service
Ilan Yaron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Ilan Yaron filed Critical Hadasit Med Res Service
Priority to IL181694A priority Critical patent/IL181694A0/en
Publication of IL181694A0 publication Critical patent/IL181694A0/en

Links

IL181694A 2007-03-04 2007-03-04 Beta glycolipids for the treatment of neurodegenerative disorders IL181694A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL181694A IL181694A0 (en) 2007-03-04 2007-03-04 Beta glycolipids for the treatment of neurodegenerative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL181694A IL181694A0 (en) 2007-03-04 2007-03-04 Beta glycolipids for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
IL181694A0 true IL181694A0 (en) 2007-07-04

Family

ID=42333851

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181694A IL181694A0 (en) 2007-03-04 2007-03-04 Beta glycolipids for the treatment of neurodegenerative disorders

Country Status (1)

Country Link
IL (1) IL181694A0 (en)

Similar Documents

Publication Publication Date Title
EP2148691A4 (en) Local complement inhibition for treatment of complement-mediated disorders
EP1976377A4 (en) Compounds for the treatment of metabolic disorders
IL197001A0 (en) Combination treatment for metabolic disorders
ZA200806074B (en) Compounds for the treatment of inflammatory disorders
EP1983972A4 (en) Compounds for the treatment of metabolic disorders
IL195203A0 (en) Compounds for the treatment of metabolic disorders
ZA201107449B (en) Compounds for the treatment of metabolic disorders
ZA201107446B (en) Compounds for the treatment of metabolic disorders
IL192852A0 (en) Compounds for the treatment of metabolic disorders
GB0904284D0 (en) Compounds for the treatment of metabolic disorders
EP2231181A4 (en) New vaccine for the treatment of mycobacterium related disorders
ZA200907827B (en) Novel combinations of neramexane for the treatment of neurodegenerative disorders
GB0809476D0 (en) Treatment of neurodegenerative disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
ZA201204391B (en) Compounds for the treatment of neurologic disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
PL1982178T3 (en) Methods for the treatment of affective disorders
IL181694A0 (en) Beta glycolipids for the treatment of neurodegenerative disorders
EP2240024A4 (en) Compounds for the treatment of metabolic disorders
ZA200807678B (en) Meridamycin analogues for the treatment of neurodegenerative disorders
IL189988A0 (en) Beta glycolipids for the treatment of neurodegenerative disorders
IL206167A0 (en) Beta glycolipids for the treatment of calcification related degenerative disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0724947D0 (en) Composition for the treatment of psychiatric disorders
IL182172A0 (en) Synthetic derivatives of beta glycolipids and compositions thereof for the treatment of pathologic disorders